Phosphodiesterase 3 and Atherosclerosis
磷酸二酯酶 3 与动脉粥样硬化
基本信息
- 批准号:7485124
- 负责人:
- 金额:$ 30.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAnti-Inflammatory AgentsAnti-inflammatoryArterial Fatty StreakAtherosclerosisC-Type Natriuretic PeptideCCL2 geneCell Adhesion MoleculesChronicCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic GMPCyclic NucleotidesDevelopmentEndothelial CellsEndotheliumEquilibriumEventFigs - dietaryFunctional disorderGene ExpressionGenetic TranscriptionHomeostasisHydrolysisIn VitroIndividualInflammatoryInflammatory ResponseMediatingMusNF-kappa BNatriuretic PeptidesNitric OxideNucleotidesOrgan Culture TechniquesPlayProcessProtein IsoformsProtein OverexpressionRegulationRoleSignal TransductionSmooth Muscle MyocytesSystemTestingTherapeutic AgentsTissue TherapyTissuesTransgenic MiceTumor Necrosis Factor-alphaVascular Cell Adhesion Molecule-1Vascular Endothelial CellVascular remodelingchemokinecytokinediethylstilbestrol monophosphatehuman TNF proteinnovel strategiesnovel therapeuticsphosphoric diester hydrolasepromoter
项目摘要
The progression of atherosclerotic lesions is believed to be a chronic inflammatory process involving vascular
remodeling of the vessel wall. There is increasing evidence that direct pathobiological events in the vessel wall play
an important role in atherosclerosis. Vascular endothelial cell (EC) and smooth muscle cell (VSMC) are both
important targets for inflammatory cytokines and also capable of producing significant amounts of cytokines,
chemokines, and adhesion molecules. The development of atherosclerosis may involve the perturbation of the
homeostatic balance between the anti-atherosclerotic signaling (such as nitric oxide (NO), C-type natriuretic
peptide (CNP), and cyclic nucleotides) and the pro-atherosclerotic signaling (such as TNF alpha and Ang II).
Cyclic nucleotide phosphodiesterases (PDEs) play critical roles in regulating intracellular cyclic nucleotide (cAMP
and cGMP) levels and compartmentalization via degradation of cyclic nucleotides. We have recently shown that
NO and CNP inhibited NF-kappaB-dependent inflammatory molecule expression in cultured VSMCs via a
cGMP-dependent inhibition of phosphodiesterase 3 (PDE3). PDE3 is the major cAMP-hydrolyzing PDE present
in VSMC and its inhibition by NO-cGMP and CNP-cGMP results in increased PKA activity, which inhibits
NF-kappaB activation and inflammatory molecule expression. Furthermore inhibition of PDE3 function
specifically blocked TNFalpha-stimulated NF-kappaB activation and inflammatory molecule expression. These
results suggest that PDE3 activity is a critical regulator of inflammatory gene expression in VSMC and that
cGMP-mediated inhibition of PDE3 activity is the mechanism of the anti-inflammatory effects of NO-cGMP and
CNP-cGMP in VSMC. To determine the role of PDE3 in the regulation of VSMC inflammatory molecule
expression and atherosclerosis formation, we propose the following three aims: Aim 1: Identify the specific isoform
of PDE3 involved in regulating NF-kappaB-dependent inflammatory molecule expression in VSMC in vitro. Aim
2: Determine the role of PDE3 in the regulation of inflammatory molecule expression in VSMC in ex vivo cultured
vessels using the organ culture system. Aim 3: Determine the effect of VSMC overexpression of a PDE3 isoform
on atherosclerosis using genetically modified mice.
动脉粥样硬化病变的进展被认为是涉及血管的慢性炎症过程,
血管壁重塑。越来越多的证据表明,直接病理生物学事件在血管壁发挥作用,
在动脉粥样硬化中的重要作用。血管内皮细胞(EC)和平滑肌细胞(VSMC)都是
是炎性细胞因子的重要靶点,也能够产生大量的细胞因子,
趋化因子和粘附分子。动脉粥样硬化的发展可能涉及微血管的扰动,
抗动脉粥样硬化信号传导(如一氧化氮(NO)、C型利钠尿肽)与抗动脉粥样硬化信号传导之间的稳态平衡
肽(CNP)和环核苷酸)和促动脉粥样硬化信号传导(如TNF α和Ang II)。
环核苷酸磷酸二酯酶(cyclicnucleotidephosphodiesterases,PDEs)在调节细胞内环核苷酸(cyclicnucleotide,cAMP)水平中起着重要作用
和cGMP)水平和通过环核苷酸降解的区室化。我们最近的研究表明
NO和CNP通过抑制VSMCs中NF-κ B依赖性炎症分子的表达,
磷酸二酯酶3(PDE 3)的cGMP依赖性抑制。PDE 3是存在的主要cAMP水解PDE
NO-cGMP和CNP-cGMP抑制VSMC的PKA活性,
NF-κ B活化和炎性分子表达。此外,抑制PDE 3功能
特异性阻断TNF α刺激的NF-κ B活化和炎性分子表达。这些
结果表明,PDE 3活性是VSMC中炎性基因表达的关键调节因子,
cGMP介导的PDE 3活性抑制是NO-cGMP抗炎作用的机制,
VSMC中的CNP-cGMP。目的:探讨PDE 3在VSMC炎症分子调节中的作用
表达与动脉粥样硬化形成的关系,我们提出以下三个目的:目的1:鉴定特异性亚型
PDE 3参与调节VSMC中NF-κ B依赖性炎症分子的表达。目的
2:确定PDE 3在离体培养的VSMC中调节炎性分子表达的作用
使用器官培养系统的容器。目的3:确定VSMC过表达PDE 3亚型的作用
动脉粥样硬化的实验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bradford C Berk其他文献
841-6 Interleukin-18 and interleukin-18 binding protein in patients with acute coronary syndromes
- DOI:
10.1016/s0735-1097(04)92143-2 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Craig R Narins;David A Lin;Zheng-Gen Jin;Bradford C Berk - 通讯作者:
Bradford C Berk
Bradford C Berk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bradford C Berk', 18)}}的其他基金
Flow responsive endothelial Pnpt1: an exoribonuclease that regulates mitochondrial function and vascular disease
流量响应内皮 Pnpt1:一种调节线粒体功能和血管疾病的核糖核酸外切酶
- 批准号:
9750410 - 财政年份:2018
- 资助金额:
$ 30.24万 - 项目类别:
PDE10A Regulation and Function in Cardiovascular Disease
PDE10A 在心血管疾病中的调节和功能
- 批准号:
9888405 - 财政年份:2017
- 资助金额:
$ 30.24万 - 项目类别:
Flow Responsive Mediators of Inflammation and Survival
炎症和生存的流量响应介质
- 批准号:
8024878 - 财政年份:2011
- 资助金额:
$ 30.24万 - 项目类别:
Flow Responsive Mediators of Inflammation and Survival
炎症和生存的流量响应介质
- 批准号:
8208041 - 财政年份:2011
- 资助金额:
$ 30.24万 - 项目类别:
Flow Responsive Mediators of Inflammation and Survival
炎症和生存的流量响应介质
- 批准号:
8588987 - 财政年份:2011
- 资助金额:
$ 30.24万 - 项目类别:
Flow Responsive Mediators of Inflammation and Survival
炎症和生存的流量响应介质
- 批准号:
8434911 - 财政年份:2011
- 资助金额:
$ 30.24万 - 项目类别:
2007 Vascular Cell Biology Gordon Research Conference
2007年血管细胞生物学戈登研究会议
- 批准号:
7273048 - 财政年份:2006
- 资助金额:
$ 30.24万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 30.24万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 30.24万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 30.24万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 30.24万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 30.24万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 30.24万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 30.24万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 30.24万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 30.24万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 30.24万 - 项目类别: